Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Ischemic Heart Disease

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 211 articles:
HTML format



Single Articles


    October 2024
  1. HEATON K, Zern EK, Spahillari A, Barrett CD, et al
    Case 34-2024: A 69-Year-Old Man with Dyspnea after Old Myocardial Infarction.
    N Engl J Med. 2024;391:1633-1641.
    PubMed    


  2. ALKAISSI H, Nazari MA, Hadrava Vanova K, Uher O, et al
    Rapid Cardiovascular Response to Belzutifan in HIF2A-Mediated Paraganglioma.
    N Engl J Med. 2024;391:1552-1555.
    PubMed    


  3. JERNBERG T
    Routine Beta-Blockers in Secondary Prevention - Approaching Retirement?
    N Engl J Med. 2024;391:1356-1357.
    PubMed    


    September 2024
  4. HABIB M, Aronson D
    Electrocardiographic Findings in Diffuse Subendocardial Ischemia.
    N Engl J Med. 2024;391:e19.
    PubMed    


  5. RUBIN EJ, Leopold J, Morrissey S
    NEJM at ESC - Invasive versus Conservative Strategy for Older Patients with Myocardial Infarction.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2410900.
    PubMed    


  6. KUNADIAN V, Mossop H, Shields C, Bardgett M, et al
    Invasive Treatment Strategy for Older Patients with Myocardial Infarction.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407791.
    PubMed     Abstract available


  7. RUBIN EJ, Leopold J, Morrissey S
    NEJM at ESC - Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2410903.
    PubMed    


  8. LIP GYH
    Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2409696.
    PubMed    


  9. CHO MS, Kang DY, Ahn JM, Yun SC, et al
    Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407362.
    PubMed     Abstract available


    August 2024
  10. RUBIN EJ, Leopold J, Morrissey S
    NEJM at ESC - Inflammation, Cholesterol, Lipoprotein(a) and 30-Year Cardiovascular Outcomes in Women.
    N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMe2410895.
    PubMed    


  11. BLUMENTHAL RS, Martin SS
    Prevention of Cardiovascular Disease - Don't Stop Thinking about Tomorrow.
    N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMe2409080.
    PubMed    


  12. RIDKER PM, Moorthy MV, Cook NR, Rifai N, et al
    Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women.
    N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2405182.
    PubMed     Abstract available


  13. SILVAIN J, Cayla G, Ferrari E, Range G, et al
    Beta-Blocker Interruption or Continuation after Myocardial Infarction.
    N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMoa2404204.
    PubMed     Abstract available


  14. RUBIN EJ, Leopold J, Morrissey S
    NEJM at ESC - Beta Blocker Interruption or Continuation with Prior Myocardial Infarction.
    N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMe2410891.
    PubMed    


  15. MAHENDIRAN T, Collet C, De Bruyne B
    More on Coronary-Artery Autoregulation with Increasing Stenosis. Reply.
    N Engl J Med. 2024;391:671.
    PubMed    


  16. YANG X, Wu M, Zhang G
    More on Coronary-Artery Autoregulation with Increasing Stenosis.
    N Engl J Med. 2024;391:670-671.
    PubMed    


    July 2024
  17. BOHM F, James S
    FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction. Reply.
    N Engl J Med. 2024;391:288.
    PubMed    


  18. LI P
    FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
    N Engl J Med. 2024;391:287-288.
    PubMed    


  19. YNDIGEGN T, Hofmann R, Jernberg T
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. Reply.
    N Engl J Med. 2024;391:95.
    PubMed    


  20. KOMAMURA K, Kobayashi K, Iwase M
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    N Engl J Med. 2024;391:94-95.
    PubMed    


  21. CLELAND JGF, McMurray JJV, Freemantle N
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    N Engl J Med. 2024;391:94.
    PubMed    


    June 2024
  22. MOLLER JE, Hassager C
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock. Reply.
    N Engl J Med. 2024;390:2328-2330.
    PubMed    


  23. VON LEWINSKI D, Herold L, Toth GG
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2328.
    PubMed    


  24. BALDETTI L, Pieri M, Scandroglio AM
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2328.
    PubMed    


  25. ELKARYONI A, Hyder O, Saad M
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2327.
    PubMed    


  26. FROM AM
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2327.
    PubMed    


  27. MALLIDI J, Lotfi A
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2326-2327.
    PubMed    


  28. THIELE H, Desch S, Zeymer U
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2325-2326.
    PubMed    


  29. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:2227.
    PubMed    


  30. MAAHS DM, Svensson J
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226-2227.
    PubMed    


  31. WENSTEDT EFE, Vogt L
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226.
    PubMed    


  32. LI S, Gu HQ, Li H, Wang X, et al
    Reteplase versus Alteplase for Acute Ischemic Stroke.
    N Engl J Med. 2024 Jun 14. doi: 10.1056/NEJMoa2400314.
    PubMed     Abstract available


  33. XIONG Y, Campbell BCV, Schwamm LH, Meng X, et al
    Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.
    N Engl J Med. 2024 Jun 14. doi: 10.1056/NEJMoa2402980.
    PubMed     Abstract available


  34. MAHENDIRAN T, Collet C, De Bruyne B
    Coronary-Artery Autoregulation with Increasing Stenosis.
    N Engl J Med. 2024;390:2030-2032.
    PubMed    


    May 2024
  35. KING G, Hamilton GW
    Left Ventricular Thrombus after Anterior Myocardial Infarction.
    N Engl J Med. 2024;390:e50.
    PubMed    


  36. NATARAJAN P
    Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease.
    N Engl J Med. 2024 May 29. doi: 10.1056/NEJMe2405647.
    PubMed    


  37. ALBERS GW, Purdon B, Campbell BCV
    Tenecteplase for Stroke at 4.5 to 24 Hours. Reply.
    N Engl J Med. 2024;390:1729.
    PubMed    


  38. GOYAL M, Bosshart SL, Ospel JM
    Tenecteplase for Stroke at 4.5 to 24 Hours.
    N Engl J Med. 2024;390:1729.
    PubMed    


  39. GRINSPOON SK, Ribaudo HJ, Douglas PS
    Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection.
    N Engl J Med. 2024;390:1626-1628.
    PubMed    


    April 2024
  40. STEG PG
    Routine Beta-Blockers in Secondary Prevention - On Injured Reserve.
    N Engl J Med. 2024;390:1434-1436.
    PubMed    


  41. RAO SV
    Mechanical Circulatory Support in Cardiogenic Shock - Persistence and Progress.
    N Engl J Med. 2024;390:1436-1438.
    PubMed    


  42. MOLLER JE, Engstrom T, Jensen LO, Eiskjaer H, et al
    Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:1382-1393.
    PubMed     Abstract available


  43. BOHM F, Mogensen B, Engstrom T, Stankovic G, et al
    FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
    N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMoa2314149.
    PubMed     Abstract available


  44. KUNADIAN V
    Role of Physiology in the Management of Nonculprit Lesions in Acute Coronary Syndrome.
    N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMe2403527.
    PubMed    


  45. YNDIGEGN T, Lindahl B, Mars K, Alfredsson J, et al
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2401479.
    PubMed     Abstract available


  46. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
    Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2402309.
    PubMed     Abstract available


  47. GIBSON CM, Duffy D, Korjian S, Bahit MC, et al
    Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2400969.
    PubMed     Abstract available


  48. ROULEAU J
    Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMe2402719.
    PubMed    


  49. BUTLER J, Jones WS, Udell JA, Anker SD, et al
    Empagliflozin after Acute Myocardial Infarction.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2314051.
    PubMed     Abstract available


  50. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:1207-1217.
    PubMed    


    March 2024
  51. WHITE HD
    A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
    N Engl J Med. 2024;390:10.
    PubMed    


  52. AL-LAMEE RK, Rajkumar CA
    A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
    N Engl J Med. 2024;390:1151-1152.
    PubMed    


  53. DURANTE A, Baiardo Redaelli M
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1150-1151.
    PubMed    


  54. SHERROD CF 4TH, O'Keefe EL, Ikemura N
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1150.
    PubMed    


  55. BESTERMANN WH JR
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1149-1150.
    PubMed    


  56. ROSWELL RO, Wong MP, Stefanescu Schmidt AC, Petranovic M, et al
    Case 8-2024: A 55-Year-Old Man with Cardiac Arrest, Cardiogenic Shock, and Hypoxemia.
    N Engl J Med. 2024;390:1030-1043.
    PubMed    


  57. CARSON JL, Brooks MM, Hebert PC
    Transfusion Strategy in Myocardial Infarction and Anemia. Reply.
    N Engl J Med. 2024;390:961-962.
    PubMed    


  58. KHAN MS, Spertus JA, Chan PS
    Transfusion Strategy in Myocardial Infarction and Anemia.
    N Engl J Med. 2024;390:960-961.
    PubMed    


  59. CHAPALAIN X, Aubron C
    Transfusion Strategy in Myocardial Infarction and Anemia.
    N Engl J Med. 2024;390:960.
    PubMed    


  60. MARFELLA R, Prattichizzo F, Sardu C, Fulgenzi G, et al
    Microplastics and Nanoplastics in Atheromas and Cardiovascular Events.
    N Engl J Med. 2024;390:900-910.
    PubMed     Abstract available


    February 2024
  61. LINCOFF AM, Ryan DH, Esbjerg S
    Semaglutide and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2024;390:768-769.
    PubMed    


  62. NEVES JS, Leite AR, Ferreira JP
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767-768.
    PubMed    


  63. CAMPBELL LA, Jenkins AV, Jackson CD
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    


  64. BELKHOURIBCHIA J
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    


  65. BELALCAZAR LM, Kuo YF
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766-767.
    PubMed    


  66. TAQUETI VR, Shaw LJ
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766.
    PubMed    


  67. ALBERS GW, Jumaa M, Purdon B, Zaidi SF, et al
    Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection.
    N Engl J Med. 2024 Feb 8. doi: 10.1056/NEJMoa2310392.
    PubMed     Abstract available


  68. LEIFER D
    Tenecteplase for Stroke - Opening the Window?
    N Engl J Med. 2024 Feb 8. doi: 10.1056/NEJMe2314930.
    PubMed    


    January 2024
  69. SPATZ ES, Ginsburg GS, Rumsfeld JS, Turakhia MP, et al
    Wearable Digital Health Technologies for Monitoring in Cardiovascular Medicine.
    N Engl J Med. 2024;390:346-356.
    PubMed    


  70. THIELE H, Desch S, Zeymer U
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. Reply.
    N Engl J Med. 2024;390:190-191.
    PubMed    


  71. SCHOLZ KH, Meyer T
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:190.
    PubMed    


  72. D'AMICO F, Pruna A, D'Andria Ursoleo J
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:190.
    PubMed    


  73. BARDY T, Didier C, Mongardon N
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:189-190.
    PubMed    


  74. STAHLI BE, Ruschitzka F
    Timing of Complete Revascularization for Myocardial Infarction. Reply.
    N Engl J Med. 2024;390:92.
    PubMed    


  75. DEN DEKKER WK, Elscot JJ, Diletti R
    Timing of Complete Revascularization for Myocardial Infarction.
    N Engl J Med. 2024;390:91-92.
    PubMed    


  76. OKHOTIN A, Barchuk A
    Timing of Complete Revascularization for Myocardial Infarction.
    N Engl J Med. 2024;390:91.
    PubMed    


    December 2023
  77. BLOCH EM, Tobian AAR
    Optimizing Blood Transfusion in Patients with Acute Myocardial Infarction.
    N Engl J Med. 2023;389:2483-2485.
    PubMed    


  78. WHITE HD
    Changing the Orbit around Percutaneous Coronary Intervention for Stable Angina.
    N Engl J Med. 2023;389:2387-2388.
    PubMed    


  79. MAGNUSSEN C, Leong DP, Blankenberg S
    Modifiable Risk Factors and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2023;389:2401-2402.
    PubMed    


  80. FIGTREE GA, Gray MP, Channon KM
    Modifiable Risk Factors and Cardiovascular Outcomes.
    N Engl J Med. 2023;389:2401.
    PubMed    


  81. MEI Z, Pu J, Zheng D
    Modifiable Risk Factors and Cardiovascular Outcomes.
    N Engl J Med. 2023;389:2400-2401.
    PubMed    


  82. OU D, Hu C, Huang S
    Modifiable Risk Factors and Cardiovascular Outcomes.
    N Engl J Med. 2023;389:2400.
    PubMed    


    November 2023
  83. GRINSPOON SK, Ribaudo HJ, Douglas PS
    Pitavastatin and Cardiovascular Disease in HIV. Reply.
    N Engl J Med. 2023;389:e46.
    PubMed    


  84. OLALLA J, Pombo M
    Pitavastatin and Cardiovascular Disease in HIV.
    N Engl J Med. 2023;389:e46.
    PubMed    


  85. IOANNOU P, Filippatos TD, Kofteridis DP
    Pitavastatin and Cardiovascular Disease in HIV.
    N Engl J Med. 2023;389:e46.
    PubMed    


  86. ALAM SR, Mureithi M, Ferrand R
    Pitavastatin and Cardiovascular Disease in HIV.
    N Engl J Med. 2023;389:e46.
    PubMed    


  87. BOETTIGER DC, Phillips AN, Newall AT
    Pitavastatin and Cardiovascular Disease in HIV.
    N Engl J Med. 2023;389:e46.
    PubMed    


  88. BISCAGLIA S, Campo G
    Complete or Culprit-Only PCI in Older Patients with MI. Reply.
    N Engl J Med. 2023;389:1924.
    PubMed    


  89. MONE P, Guerra G, Santulli G
    Complete or Culprit-Only PCI in Older Patients with MI.
    N Engl J Med. 2023;389:1923-1924.
    PubMed    


  90. SANCHIS J, Ariza-Sole A, Alfonso F
    Complete or Culprit-Only PCI in Older Patients with MI.
    N Engl J Med. 2023;389:1923.
    PubMed    


  91. DURAI V, Mallidi J
    Complete or Culprit-Only PCI in Older Patients with MI.
    N Engl J Med. 2023;389:1922.
    PubMed    


  92. MADSEN JM, Engstrom T
    Complete or Culprit-Only PCI in Older Patients with MI.
    N Engl J Med. 2023;389:1922-1923.
    PubMed    


  93. LINCOFF AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563.
    PubMed     Abstract available


  94. KHERA A, Powell-Wiley TM
    SELECTing Treatments for Cardiovascular Disease - Obesity in the Spotlight.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMe2312646.
    PubMed    


  95. CARSON JL, Brooks MM, Hebert PC, Goodman SG, et al
    Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307983.
    PubMed     Abstract available


  96. RAJKUMAR CA, Foley MJ, Ahmed-Jushuf F, Nowbar AN, et al
    A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2310610.
    PubMed     Abstract available


    October 2023
  97. HOLM NR, Andreasen LN, Neghabat O, Laanmets P, et al
    OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions.
    N Engl J Med. 2023;389:1477-1487.
    PubMed     Abstract available


  98. JONES WS
    Timing Is Everything - Evidence for When to Perform Complete Revascularization in STEMI.
    N Engl J Med. 2023;389:1427-1428.
    PubMed    


  99. JOSEPH P, Yusuf S
    Coordinating Efforts to Reduce the Global Incidence of Cardiovascular Disease.
    N Engl J Med. 2023;389:1329-1331.
    PubMed    


    September 2023
  100. BHASIN S, Lincoff AM, Nissen SE
    Cardiovascular Safety of Testosterone-Replacement Therapy. Reply.
    N Engl J Med. 2023;389:1150-1151.
    PubMed    


  101. GROSSMANN M, Zajac JD
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023;389:1149-1150.
    PubMed    


  102. MALOZOWSKI S, Reboussin DM
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023;389:1149.
    PubMed    


  103. HUANG Y, Shen B, Zhou YF
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023;389:1148-1149.
    PubMed    


    August 2023
  104. STAHLI BE, Varbella F, Linke A, Schwarz B, et al
    Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction.
    N Engl J Med. 2023 Aug 27. doi: 10.1056/NEJMoa2307823.
    PubMed     Abstract available


  105. ALI ZA, Landmesser U, Maehara A, Matsumura M, et al
    Optical Coherence Tomography-Guided versus Angiography-Guided PCI.
    N Engl J Med. 2023 Aug 27. doi: 10.1056/NEJMoa2305861.
    PubMed     Abstract available


  106. BISCAGLIA S, Guiducci V, Escaned J, Moreno R, et al
    Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMoa2300468.
    PubMed     Abstract available


  107. MEHTA SR
    Complete Revascularization in Older Patients with Myocardial Infarction.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMe2307941.
    PubMed    


  108. MAGNUSSEN C, Ojeda FM, Leong DP, Alegre-Diaz J, et al
    Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMoa2206916.
    PubMed     Abstract available


  109. THIELE H, Zeymer U, Akin I, Behnes M, et al
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMoa2307227.
    PubMed     Abstract available



  110. Preventing HIV's Collateral Cardiovascular Damage.
    N Engl J Med. 2023;389:e11.
    PubMed    


    July 2023
  111. GRINSPOON SK, Fitch KV, Zanni MV, Fichtenbaum CJ, et al
    Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.
    N Engl J Med. 2023 Jul 23. doi: 10.1056/NEJMoa2304146.
    PubMed     Abstract available


  112. FREIBERG MS
    HIV and Cardiovascular Disease - An Ounce of Prevention.
    N Engl J Med. 2023 Jul 23. doi: 10.1056/NEJMe2306782.
    PubMed    


    June 2023
  113. NISSEN SE, Nicholls SJ, Lincoff AM
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2023;388:2489-2490.
    PubMed    


  114. AMARENCO P
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes.
    N Engl J Med. 2023;388:2488-2489.
    PubMed    


  115. STEINACHER E, Sulzgruber P, Niessner A
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes.
    N Engl J Med. 2023;388:2488.
    PubMed    


  116. SPACEK L
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes.
    N Engl J Med. 2023;388:2488.
    PubMed    


  117. LOPEZ-AYALA P, Glarner N, Mueller C
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes.
    N Engl J Med. 2023;388:2487-2488.
    PubMed    


  118. LINCOFF AM, Bhasin S, Flevaris P, Mitchell LM, et al
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023 Jun 16. doi: 10.1056/NEJMoa2215025.
    PubMed     Abstract available


    May 2023
  119. LEE JM, Choi KH, Song YB, Lee JY, et al
    Intravascular Imaging-Guided or Angiography-Guided Complex PCI.
    N Engl J Med. 2023;388:1668-1679.
    PubMed     Abstract available


    April 2023
  120. ISHANI A, Cushman WC, Leatherman SM
    Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. Reply.
    N Engl J Med. 2023;388:1342.
    PubMed    


  121. FRAVEL MA, Ernst ME
    Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
    N Engl J Med. 2023;388:1342.
    PubMed    


  122. MESSERLI FH
    Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
    N Engl J Med. 2023;388:1341-1342.
    PubMed    


    March 2023
  123. JABAGI MJ, Bertrand M, Botton J, Le Vu S, et al
    Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster.
    N Engl J Med. 2023 Mar 29. doi: 10.1056/NEJMc2302134.
    PubMed    


  124. OLIVA-DAMASO N, Perazella MA
    Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    N Engl J Med. 2023;388:955.
    PubMed    


  125. VAN REGEMORTER E, Jadoul M, Gillion V
    Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    N Engl J Med. 2023;388:954-955.
    PubMed    


  126. KEANEY JF JR
    Bempedoic Acid and the Prevention of Cardiovascular Disease.
    N Engl J Med. 2023 Mar 4. doi: 10.1056/NEJMe2300793.
    PubMed    


  127. NISSEN SE, Lincoff AM, Brennan D, Ray KK, et al
    Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
    N Engl J Med. 2023 Mar 4. doi: 10.1056/NEJMoa2215024.
    PubMed     Abstract available


    January 2023
  128. PERERA D, Ryan M, O'Kane PD
    PCI for Ischemic Left Ventricular Dysfunction. Reply.
    N Engl J Med. 2023;388:188-189.
    PubMed    


  129. ALFONSO F, Cuesta J, Diez-Villanueva P
    PCI for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2023;388:188.
    PubMed    


  130. ANDREOTTI F, Chiariello GA, Massetti M
    PCI for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2023;388:187-188.
    PubMed    


  131. VIDAL-CALES P, Brugaletta S, Sabate M
    PCI for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2023;388:187.
    PubMed    


  132. DE SILVA K, Campbell T, Kumar S
    PCI for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2023;388:186-187.
    PubMed    


    December 2022
  133. GUSEH JS 2ND, Parakh A, Chen YE, Sundt TM, et al
    Case 40-2022: A 38-Year-Old Man with Exertional Chest Discomfort.
    N Engl J Med. 2022;387:2450-2460.
    PubMed    


  134. MC CAUSLAND FR, Singh AK, Claggett BL, Carroll K, et al
    Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply.
    N Engl J Med. 2022;387:2482-2485.
    PubMed    


  135. HUANG C, He Y, Li Y
    Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease.
    N Engl J Med. 2022;387:2482.
    PubMed    


  136. ROJAS-RIVERA J, Carriazo S, Ortiz A
    Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease.
    N Engl J Med. 2022;387:2481-2482.
    PubMed    


  137. ISHANI A, Cushman WC, Leatherman SM, Lew RA, et al
    Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
    N Engl J Med. 2022 Dec 14. doi: 10.1056/NEJMoa2212270.
    PubMed     Abstract available


  138. CASTELLANO JM, Cordero A, Fuster V
    Polypill Strategy in Secondary Cardiovascular Prevention. Reply.
    N Engl J Med. 2022;387:2197-2198.
    PubMed    


  139. ZHANG Y, Zhu Z, Gao C
    Polypill Strategy in Secondary Cardiovascular Prevention.
    N Engl J Med. 2022;387:2197.
    PubMed    


  140. CARNEY RM, Freedland KE
    Polypill Strategy in Secondary Cardiovascular Prevention.
    N Engl J Med. 2022;387:2197.
    PubMed    


  141. STOSCHITZKY K
    Polypill Strategy in Secondary Cardiovascular Prevention.
    N Engl J Med. 2022;387:2196-2197.
    PubMed    


    November 2022
  142. PARK DW, Kang DY, Park SJ
    Stress Testing in High-Risk Patients after PCI. Reply.
    N Engl J Med. 2022;387:e54.
    PubMed    


  143. SHIOMI H
    Stress Testing in High-Risk Patients after PCI.
    N Engl J Med. 2022;387:e54.
    PubMed    


  144. O'DONOGHUE ML, Rosenson RS, Gencer B, Lopez JAG, et al
    Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
    N Engl J Med. 2022 Nov 6. doi: 10.1056/NEJMoa2211023.
    PubMed     Abstract available


  145. DAS PRADHAN A, Glynn RJ, Fruchart JC, MacFadyen JG, et al
    Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    N Engl J Med. 2022 Nov 5. doi: 10.1056/NEJMoa2210645.
    PubMed     Abstract available



  146. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction.
    N Engl J Med. 2022;387:1724.
    PubMed    


    October 2022
  147. DESAI AS, Dudzinski DM, Stib MT, Chen ST, et al
    Case 32-2022: A 76-Year-Old Man with Postoperative Cardiogenic Shock and Diffuse Rash.
    N Engl J Med. 2022;387:1502-1513.
    PubMed    


  148. PERERA D, Clayton T, O'Kane PD, Greenwood JP, et al
    Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2022;387:1351-1360.
    PubMed     Abstract available


    September 2022

  149. Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;387:1244.
    PubMed    


  150. HONDA S, Kawasaki T
    Wellens' Syndrome.
    N Engl J Med. 2022;387:e25.
    PubMed    


  151. RYDEN L, Standl E
    After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk.
    N Engl J Med. 2022;387:1136-1138.
    PubMed    


  152. NATHAN DM, Lachin JM, Bebu I, Burch HB, et al
    Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    N Engl J Med. 2022;387:1075-1088.
    PubMed     Abstract available


  153. FUKAMACHI D, Okumura Y
    Giant Coronary-Artery Aneurysm.
    N Engl J Med. 2022;387:e23.
    PubMed    


  154. PARK DW, Kang DY, Ahn JM, Yun SC, et al
    Routine Functional Testing or Standard Care in High-Risk Patients after PCI.
    N Engl J Med. 2022;387:905-915.
    PubMed     Abstract available


  155. TAMIS-HOLLAND JE
    Surveillance Stress Testing "POST-PCI" - A Future Class III Recommendation?
    N Engl J Med. 2022;387:941-942.
    PubMed    


  156. KOO BK, Hu X, Kang J, Zhang J, et al
    Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI.
    N Engl J Med. 2022;387:779-789.
    PubMed     Abstract available


    August 2022
  157. LINDHOLT JS, Sogaard R, Rasmussen LM, Mejldal A, et al
    Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMoa2208681.
    PubMed     Abstract available


  158. CASTELLANO JM, Pocock SJ, Bhatt DL, Quesada AJ, et al
    Polypill Strategy in Secondary Cardiovascular Prevention.
    N Engl J Med. 2022 Aug 26. doi: 10.1056/NEJMoa2208275.
    PubMed     Abstract available


  159. LESLIE BR, Gerwin LE
    Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;387:478.
    PubMed    


  160. HEYMAN SN, Abassi Z
    Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;387:477-478.
    PubMed    


  161. JACOBS DR JR, Sinaiko AR, Woo JG
    Childhood Risk Factors and Adult Cardiovascular Events. Reply.
    N Engl J Med. 2022;387:473-474.
    PubMed    


  162. SCHUERMANS A, Lewandowski AJ
    Childhood Risk Factors and Adult Cardiovascular Events.
    N Engl J Med. 2022;387:473.
    PubMed    


  163. WANG M, Zhou M, Feng Z
    Childhood Risk Factors and Adult Cardiovascular Events.
    N Engl J Med. 2022;387:472-473.
    PubMed    


  164. ORTIZ A
    Childhood Risk Factors and Adult Cardiovascular Events.
    N Engl J Med. 2022;387:472.
    PubMed    


    July 2022
  165. DODD JD, Kofoed KF, Dewey M
    CT or Invasive Coronary Angiography in Stable Chest Pain. Reply.
    N Engl J Med. 2022;387:379-380.
    PubMed    


  166. GIBBONS RJ
    CT or Invasive Coronary Angiography in Stable Chest Pain.
    N Engl J Med. 2022;387:378.
    PubMed    


  167. DANZI GB, Piccolo R
    CT or Invasive Coronary Angiography in Stable Chest Pain.
    N Engl J Med. 2022;387:378.
    PubMed    


  168. BAUMANN AA, Roberts-Thomson RL, Psaltis PJ
    CT or Invasive Coronary Angiography in Stable Chest Pain.
    N Engl J Med. 2022;387:377-378.
    PubMed    


  169. REDBERG R, Jeon D
    CT or Invasive Coronary Angiography in Stable Chest Pain.
    N Engl J Med. 2022;387:376-377.
    PubMed    


    June 2022
  170. MA Y, Cook NR, Hu FB
    Daily Urinary Sodium and Potassium Excretion and Cardiovascular Risk. Reply.
    N Engl J Med. 2022;386:e60.
    PubMed    


  171. IOANNOU A
    Daily Urinary Sodium and Potassium Excretion and Cardiovascular Risk.
    N Engl J Med. 2022;386:e60.
    PubMed    


  172. LIU L, Chen Y, Liu S
    Daily Urinary Sodium and Potassium Excretion and Cardiovascular Risk.
    N Engl J Med. 2022;386:e60.
    PubMed    


  173. INOUE K, Nishikawa T
    Daily Urinary Sodium and Potassium Excretion and Cardiovascular Risk.
    N Engl J Med. 2022;386:e60.
    PubMed    


    May 2022
  174. BRAUNWALD E
    Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;386:2024-2034.
    PubMed    


  175. FEARON WF, Zimmermann FM, Pijls NHJ
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. Reply.
    N Engl J Med. 2022;386:1865-1866.
    PubMed    


  176. FERLINI M, Munafo A, Visconti LO
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:1865.
    PubMed    


  177. FELDMAN D, Nicolas J, Dangas G
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:1864-1865.
    PubMed    


  178. ROSENBLUM AL, Pack QR
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:1864.
    PubMed    


  179. VAN BELLE E, Patel M, Davies J
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:1863-1864.
    PubMed    


  180. YTTERBERG SR, Bhatt DL, Connell CA
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply.
    N Engl J Med. 2022;386:1768.
    PubMed    


  181. D'AMICO F, Peyrin-Biroulet L, Danese S
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    N Engl J Med. 2022;386:1767-1768.
    PubMed    


  182. LADAK K, Crowther M
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    N Engl J Med. 2022;386:1766-1767.
    PubMed    


  183. OZDEDE A, Yazici H
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    N Engl J Med. 2022;386:1766.
    PubMed    


    April 2022
  184. PITT B, Joseph A, Schloemer P
    Cardiovascular Events with Finerenone in CKD and Diabetes. Reply.
    N Engl J Med. 2022;386:e43.
    PubMed    


  185. ORTIZ A, Sarafidis P, Ferro CJ
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    PubMed    


  186. GERARD AO, Laurain A, Esnault VLM
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    PubMed    


  187. KAO PH, Hsu LC
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    PubMed    


  188. INGELFINGER JR
    Childhood Risk Factors and Prediction of Adult Cardiovascular End Points.
    N Engl J Med. 2022 Apr 4. doi: 10.1056/NEJMe2203743.
    PubMed    


  189. JACOBS DR JR, Woo JG, Sinaiko AR, Daniels SR, et al
    Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events.
    N Engl J Med. 2022 Apr 4. doi: 10.1056/NEJMoa2109191.
    PubMed     Abstract available


    March 2022
  190. MAUROVICH-HORVAT P, Bosserdt M, Kofoed KF, Rieckmann N, et al
    CT or Invasive Coronary Angiography in Stable Chest Pain.
    N Engl J Med. 2022 Mar 4. doi: 10.1056/NEJMoa2200963.
    PubMed     Abstract available


  191. DEVEREAUX PJ, Lamy A, Chan MTV, Allard RV, et al
    High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality.
    N Engl J Med. 2022;386:827-836.
    PubMed     Abstract available


    February 2022
  192. PFEFFER MA, Jering KS, Braunwald E
    Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. Reply.
    N Engl J Med. 2022;386:603.
    PubMed    


  193. IOANNOU A
    Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    N Engl J Med. 2022;386:603.
    PubMed    


    January 2022
  194. YTTERBERG SR, Bhatt DL, Mikuls TR, Koch GG, et al
    Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    N Engl J Med. 2022;386:316-326.
    PubMed     Abstract available


  195. FEARON WF, Zimmermann FM, De Bruyne B, Piroth Z, et al
    Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
    N Engl J Med. 2022;386:128-137.
    PubMed     Abstract available


    December 2021

  196. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    N Engl J Med. 2021;385:2592.
    PubMed    


  197. DESCH S, Freund A, Akin I, Behnes M, et al
    Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation.
    N Engl J Med. 2021;385:2544-2553.
    PubMed     Abstract available


  198. NEAL B, Tian M, Wu Y
    Salt Substitute and Cardiovascular Events and Death. Reply.
    N Engl J Med. 2021;385:2493-2494.
    PubMed    


  199. BURSZTYN M
    Salt Substitute and Cardiovascular Events and Death.
    N Engl J Med. 2021;385:2493.
    PubMed    


  200. MORITA H, Komuro I
    Salt Substitute and Cardiovascular Events and Death.
    N Engl J Med. 2021;385:2492-2493.
    PubMed    


  201. ZUCCALA G, Laudisio A, Ciaburri M
    Salt Substitute and Cardiovascular Events and Death.
    N Engl J Med. 2021;385:2492.
    PubMed    


  202. GRAUDAL N, Jurgens G, Alderman MH
    Salt Substitute and Cardiovascular Events and Death.
    N Engl J Med. 2021;385:2491-2492.
    PubMed    


    November 2021
  203. MATHEW R, Di Santo P, Hibbert B
    Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock. Reply.
    N Engl J Med. 2021;385:2108-2109.
    PubMed    


  204. GIBSON LE, Chang MG, Berra L
    Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
    N Engl J Med. 2021;385:2108.
    PubMed    


  205. POTTER BJ
    Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
    N Engl J Med. 2021;385:2107-2108.
    PubMed    


  206. MA Y, He FJ, Sun Q, Yuan C, et al
    24-Hour Urinary Sodium and Potassium Excretion and Cardiovascular Risk.
    N Engl J Med. 2021 Nov 13. doi: 10.1056/NEJMoa2109794.
    PubMed     Abstract available


  207. PFEFFER MA, Claggett B, Lewis EF, Granger CB, et al
    Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    N Engl J Med. 2021;385:1845-1855.
    PubMed     Abstract available


  208. SINGH AK, Carroll K, McMurray JJV, Solomon S, et al
    Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
    N Engl J Med. 2021 Nov 5. doi: 10.1056/NEJMoa2113380.
    PubMed     Abstract available


  209. SINGH AK, Carroll K, Perkovic V, Solomon S, et al
    Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
    N Engl J Med. 2021 Nov 5. doi: 10.1056/NEJMoa2113379.
    PubMed     Abstract available


    October 2021
  210. VALGIMIGLI M, Frigoli E, Heg D, Tijssen J, et al
    Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.
    N Engl J Med. 2021;385:1643-1655.
    PubMed     Abstract available



  211. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
    N Engl J Med. 2021;385:1632.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.